Patents by Inventor Cuishuan WU

Cuishuan WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONCENTRATE CONTAINING POORLY SOLUBLE DRUG AND EMULSION PREPARED THEREFROM
    Publication number: 20230398072
    Abstract: A concentrate, characterized in that the concentrate contains a poorly soluble drug and a self-emulsifying carrier. The selfemulsifying carrier consists of the following substances: a composite emulsifier, which consists of phospholipid and nonphospholipid emulsifiers; an oil, which is medium chain triglyceride; and a co-emulsifier, which is anhydrous ethanol. The phospholipid is selected from soybean phospholipid, egg yolk lecithin, and a mixture thereof. The concentrate can be used to prepare an intravenous injection emulsion.
    Type: Application
    Filed: December 10, 2021
    Publication date: December 14, 2023
    Applicant: BEIJING DELIVERY PHARMACEUTICAL TECHNOLOGY CO., LTD
    Inventors: Cuishuan WU, Xiaobo CHENG, Dan ZHANG, Jixiang HOU, Boce ZHAO, Qiang ZHANG
  • Long-circulating liposome modified with c(RGD-ACP-K)
    Patent number: 11260068
    Abstract: The present invention relates to a long-circulating liposome modified with c(RGD-ACP-K). The present invention pertains to the field of pharmaceutical preparations, in particular to the field of targeted pharmaceutical preparations. More specifically, the present invention relates to a long-circulating liposome, the surface of the liposome being modified with c(RGD-ACP-K), and the liposome comprising doxorubicin or a pharmaceutically acceptable salt thereof such as doxorubicin hydrochloride as an anti-cancer active agent. The long-circulating liposome can targetedly deliver the anti-cancer active agent into tumor neovascular endothelial cells and tumor cells and can prolong the circulation time of the liposome in vivo, thereby enhancing the therapeutic effect of anti-tumor medicaments.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 1, 2022
    Assignee: BEIJING GREATSUN BTO-PHARM. TECH. CO., LTD
    Inventors: Qiang Zhang, Cuishuan Wu, Yue Su, Changjin Lee, Guanghua Cui
  • LONG-CIRCULATING LIPOSOME MODIFIED WITH C(RGD-ACP-K)
    Publication number: 20200197424
    Abstract: The present invention relates to a long-circulating liposome modified with c(RGD-ACP-K). The present invention pertains to the field of pharmaceutical preparations, in particular to the field of targeted pharmaceutical preparations. More specifically, the present invention relates to a long-circulating liposome, the surface of the liposome being modified with c(RGD-ACP-K), and the liposome comprising doxorubicin or a pharmaceutically acceptable salt thereof such as doxorubicin hydrochloride as an anti-cancer active agent. The long-circulating liposome can targetedly deliver the anti-cancer active agent into tumor neovascular endothelial cells and tumor cells and can prolong the circulation time of the liposome in vivo, thereby enhancing the therapeutic effect of anti-tumor medicaments.
    Type: Application
    Filed: May 24, 2018
    Publication date: June 25, 2020
    Inventors: Qiang ZHANG, Cuishuan WU, Yue SU, Changjin LEE, Guanghua CUI